文献速递精神分裂症与精神病性障碍

神经递质通路多基因风险与精神病症状特征的关联

Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis.
PubMed 文献 · Mol Psychiatry · 2024-03-15

该研究纳入205例早期精神病患者和115名匹配对照,计算精神分裂症和双相障碍多基因评分及四种神经递质通路特异性评分。结果显示患者精神分裂症多基因评分升高,谷氨酸通路评分与精神分裂症诊断及认知控制缺陷相关,多巴胺通路评分与整体功能相关,通路分析有助于解析遗传风险与内表型的关联。

要点

  • 精神病患者精神分裂症多基因评分高于对照,诊断与相应多基因风险对应。
  • 谷氨酸通路评分与精神分裂症诊断及任务态fMRI认知控制缺陷相关。
  • 多巴胺通路评分与整体功能相关,内表型聚类显示谷氨酸/GABA能通路特异性风险。

核心结论

  • 基于通路的PGS分析可能有助于研究驱动精神疾病内表型的遗传机制。

研究设计与样本

  • 纳入205例早期精神病患者和115名匹配对照,进行精神病学和神经学表型评估及基因分型。
  • 计算精神分裂症和双相障碍总体PGS,以及谷氨酸、GABA、多巴胺、5-羟色胺四种通路特异性PGS。

主要发现

  • 精神病患者精神分裂症PGS高于对照,精神分裂症或双相障碍诊断分别与相应疾病PGS关联更强。
  • 在精神病患者内,个体症状测量与总体PGS无显著关联。
  • 谷氨酸通路pPGS与精神分裂症诊断及任务态fMRI认知控制缺陷相关,多巴胺通路pPGS与整体功能相关。
  • 无偏内表型驱动聚类识别出三个诊断混合的病例组,均显示强全基因组风险;第2组以认知控制和阴性症状缺陷为特征,风险集中于谷氨酸能和GABA能通路。

临床怎么用

  • 通路特异性PGS分析可为理解精神病遗传机制与内表型关联提供线索。
  • 谷氨酸通路风险可能与认知控制缺陷相关,多巴胺通路风险可能与整体功能相关。

局限性

  • 因受试者深度表征,研究限于相对较小的队列。
  • 结果需在人群和机制层面进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A primary goal of psychiatry is to better understand the pathways that link genetic risk to psychiatric symptoms. Here, we tested association of diagnosis and endophenotypes with overall and neurotransmitter pathway-specific polygenic risk in patients with early-stage psychosis. Subjects included 205 demographically diverse cases with a psychotic disorder who underwent comprehensive psychiatric and neurological phenotyping and 115 matched controls. Following genotyping, we calculated polygenic scores (PGSs) for schizophrenia (SZ) and bipolar disorder (BP) using Psychiatric Genomics Consortium GWAS summary statistics. To test if overall genetic risk can be partitioned into affected neurotransmitter pathways, we calculated pathway PGSs (pPGSs) for SZ risk affecting each of four major neurotransmitter systems: glutamate, GABA, dopamine, and serotonin. Psychosis subjects had elevated SZ PGS versus controls; cases with SZ or BP diagnoses had stronger SZ or BP risk, respectively. There was no significant association within psychosis cases between individual symptom measures and overall PGS. However, neurotransmitter-specific pPGSs were moderately associated with specific endophenotypes; notably, glutamate was associated with SZ diagnosis and with deficits in cognitive control during task-based fMRI, while dopamine was associated with global functioning. Finally, unbiased endophenotype-driven clustering identified three diagnostically mixed case groups that separated on primary deficits of positive symptoms, negative symptoms, global functioning, and cognitive control. All clusters showed strong genome-wide risk. Cluster 2, characterized by deficits in cognitive control and negative symptoms, additionally showed specific risk concentrated in glutamatergic and GABAergic pathways. Due to the intensive characterization of our subjects, the present study was limited to a relatively small cohort. As such, results should be followed up with additional research at the population and mechanism level. Our study suggests pathway-based PGS analysis may be a powerful path forward to study genetic mechanisms driving psychiatric endophenotypes.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Warren TL, Tubbs JD, Lesh TA, et al. Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis. Mol Psychiatry. 2024. PMID: 38491343. doi:10.1038/s41380-024-02457-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。